There is endless profit potential to treat chronic diseases
I have noticed several articles describing how antibiotic development has bankrupted some pharmaceutical companies because there isn’t enough potential profit in a ten-day course to treat multi-resistant superbug infections.
Chronic disease treatments, on the other hand, appear to be extremely profitable. A single month’s treatment with the newer diabetes drugs, COPD inhalers, or blood thinners costs over $500, which means well over $50,000 over an effective ten year patent for each …
There is endless profit potential to treat chronic diseases
















![Why weight regain is a predictable biological response after stopping GLP-1s [PODCAST]](https://kevinmd.com/wp-content/uploads/662faf85-c18d-47d3-8970-8f0e4231882f-190x100.jpeg)



![Politics and fear have replaced science in U.S. pain management [PODCAST]](https://kevinmd.com/wp-content/uploads/11c2db8f-2b20-4a4d-81cc-083ae0f47d6e-190x100.jpeg)






